Enzyme-Directed Pro-lmmunostimulants for Cancer Therapy Targeting of pro-immunostimulants to tumor environments Cancer treatments could be optimized through more effective ways of targeting immunostimulants to tumor environments. Current immunotherapies are limited to direct intra-tumoural infusion, due to severe inflammatory toxicity that results from systemic routes of administration. Directed Enzyme Prodrug Therapy (DEPT) is an approach that couples a drug with a substrate, together the prodrug, where the drug is not active until the substrate has been cleaved off. A DEPT approach for the delivery of an immunostimulant to a cancerous region would prevent problems associated with inflammatory toxicity, providing a localized immune response directed towards the cancerous region. Researchers at WSU have developed a pro-immunostimulant for cancer therapy that is only released in relevant concentrations in regions where there is cancerous activity. Once released it activates a robust, innate immune response in the region through enzyme directed substrate cleavage and immunostimulant release. A few robustly activated immune cells go on to activate bystander immune cells in the tumor microenvironment, resulting in a localized immune response. This not only allows for directed therapy but also greatly reduces off target cytotoxicity that is common in this class of therapeutics – as activated immune cells can only activate more immune cells, we are not dropping cytotoxic loads that can damage non-cancerous cells. Because this treatment relies on the activation/enhancement of natural mechanisms, it can be used in conjunction with existing chemotherapies. Applications and Advantages• Targeted activation of the immune response that prevents problems associated with inflammatory toxicity due to systemic approaches• Activates robust natural tumor suppression pathways, allowing use in conjunction with existing chemotherapies• Takes advantage of the bystander effect by activating a few immune cells (in a cancerous environment) which go on to activate other immune cells in that environment Learn More Punam Dalai Technology Licensing Associate Washington State University (509) 335-1216 punam.dalai@wsu.edu Reference No: 1734 Bookmark this page Download as PDF Inventors Rock Mancini Amy Nielsen Joseph Hantho Anthony Burt Austin Ryan Key Words Cancer metastasis Immunotherapy